NCT03364621Active, not recruiting
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 17 (actual)
- First submitted
- 9 Nov 2017
- Start date
- 29 Aug 2017
- Primary completion date
- 29 Jun 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Colorectal cancer
- NCT number
- NCT03364621
What you commit to
- Study type: Observational
- Participants enrolled: 17
- From 29 Aug 2017 to the primary completion date, 29 Jun 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with un-resectable or borderline resectable isolated liver metastases as judged by the multidisciplinary hepatobiliary tumor board at PM or BCCA after a course of pre-operative chemotherapy will be excluded
- Patients with any major co-morbidity or co-morbidities that will render liver resection very high risk in investigator's opinion
- Patients with a previous history of another primary cancer treated within 5 years of study entry are not eligible except those with basal cell or squamous cell carcinoma of the skin and intraepithelial neoplasia.
Other illness
- Patients with evidence of possible metastatic disease at any sites outside the liver are not eligible
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Criteria the registry did not label
- Eligibility Criteria:
- Patients must have histologically confirmed CRC with isolated liver metastasis
- Patients must be planned for a hepatic metastasectomy
- Patients must have received at least 3 cycles of chemotherapy (FOLFOX or FOLFIRI with or without Bevacizumab) prior to the planned hepatic metastasectomy
- Primary tumor must be considered resectable with a plan for this to either occur concurrently with the liver resection or subsequent to this.
- If primary has already been resected before liver resection, archival tissue must be available for genomic analysis
- Patients must be 18yrs of age or older
- Ability to understand and willing to sign a written informed consent document
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| Vancouver Regional Cancer Centre Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.